cd19 universal car-γδ t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06106893)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06106893 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Guangzhou Bio-gene Technology Co., Ltd., Huazhong University of Science and Technology, Wuhan Union Hospital, China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Wuhan Union Hospital, China | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1